Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry
Resolved · market structure · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-06. Check what remains unresolved below before relying on it.
What changed relative to expectations?
Capital equipment order deceleration compresses ISRG's forward EV/EBITDA multiple despite resilient 75% recurring service cash flows.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factIntuitive Surgical shares have pulled back 40% from recent high levels. |
| What else was confirmed? | Reported factSales growth for da Vinci surgical systems has cooled due to competition from Medtronic and Johnson & Johnson. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for ISRG; the latest is dated 2026-09-06. |
| What would change the assessment? | UnknownQuarterly Hospital da Vinci System Placement Figures — Net new surgical robot installations versus MDT Hugo and JNJ Ottava competitive wins |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Intuitive Surgical shares have pulled back 40% from recent high levels.
- · Sales growth for da Vinci surgical systems has cooled due to competition from Medtronic and Johnson & Johnson.
- · Recurring revenue from instruments, accessories, and services accounts for 75% of total Intuitive Surgical revenue.
Public research record
Research framework · page evidenceCompleted event assessment
multiple re-rating from slowing system unit sales balanced by 75% recurring service cash flow
| Type | Claim | Scope |
|---|---|---|
| Assumption | Intuitive Surgical shares have pulled back 40% from recent high levels. | 2026-09-06 |
| Interpretation | multiple re-rating from slowing system unit sales balanced by 75% recurring service cash flow | ISRG |
Countercase, invalidators, and sources
Procedure volume acceleration expands recurring instrument pull-through above 80% of revenue.
- · Quarterly Hospital da Vinci System Placement Figures — Net new surgical robot installations versus MDT Hugo and JNJ Ottava competitive wins
- Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning? · 2026-09-05
What remains unresolved
- Base path
- System installations remain subdued as hospital capex scrutiny persists alongside competitive trialing.
- Adverse path
- Rival platforms gain material enterprise hospital contracts, eroding core consumables margin pricing power.
- Supportive path
- Procedure volume acceleration expands recurring instrument pull-through above 80% of revenue.
- · Quarterly Hospital da Vinci System Placement Figures — Net new surgical robot installations versus MDT Hugo and JNJ Ottava competitive winsnext month
Evidence
- Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?2026-09-05
“Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, the company's core business model relies on recurring revenue from parts and services (75% of revenue)...”
Supports: ISRG stock declined 40% amid competition from MDT and JNJ, with recurring revenue at 75%.